BioPharmSignal logoBioPharmSignal

Biotech News

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Cabaletta Bio (CABA)Cabaletta BioCommercial

CABA (CABA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is caba.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

CABACabaletta Bio2026-06-03 11:00 EST

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

KYTXKyverna Therapeutics2026-07-27 12:00 EST

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

INMBINmune Bio2026-07-20 11:00 EST

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

KYTXKyverna Therapeutics2026-06-22 12:00 EST

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

HCWBHCW Biologics2026-05-27 11:45 EST

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

CABACabaletta Bio2026-08-13 11:30 EST

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

CUECue Biopharma Inc2026-06-02 20:05 EST

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

MREOMereo BioPharma2026-08-11 12:00 EST

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

View all latest news

Cabaletta Bio

Autoimmune Cell Therapy Company Cabaletta Bio develops engineered T-cell therapies intended to produce deep and durable responses in autoimmune disease. Rese-cel Rese-cel is a fully human CD19-directed CAR T-cell therapy being studied across myositis, systemic lupus erythematosus, systemic sclerosis, and pemphigus vulgaris. CARTA...

Recent company news

CABACabaletta Bio2026-08-13 11:30 EST

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-06-03 11:00 EST

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

CABACabaletta Bio2026-05-14 11:05 EST

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

CABACabaletta Bio2026-05-14 11:00 EST

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

CABACabaletta Bio2026-05-04 10:35 EST

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Stock data

Close
3.13 USD
Market cap
600.04M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States